CJC-1295 No DAC 5mg + Ipamorelin 5mg (10mg Blend) Dosage Protocol
Contents
- Quickstart Highlights
- Dosing & Reconstitution Guide
- Standard Gradual Protocol (2.0 mL = ~5 mg/mL)
- Combined Stack Schedule
- Reconstitution Steps
- Supplies Needed
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Important Notes
- How This Works
- Potential Benefits & Side Effects
- Lifestyle Factors
- Injection Technique
- Recommended Source
- Important Note
- References
Quickstart Highlights
This research blend combines CJC-1295 (No DAC), a modified growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue (GHS). Together, these compounds are commonly studied for their ability to support natural growth hormone signaling pathways.
CJC-1295 (No DAC) is known for producing sustained, dose-dependent increases in growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. Ipamorelin works synergistically by stimulating GH release in a highly selective manner, without significantly impacting ACTH or cortisol levels.
When used together, these compounds support increased GH and IGF-1 levels through complementary pathways, resulting in a more sustained and efficient hormonal response.
This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.
Reconstitution & Basic Usage
- Reconstitute: Add 2.0 ml bacteriostatic water → ~5 mg/mL total concentration (2.5 mg/mL each peptide).
- Typical daily range: 500 mcg (250 mcg of each peptide) once daily (gradual titration).
- Easy measuring: At 5 mg/ml total, 1 unit = 0.01 ml ≈ (50 mcg) 25 mcg of each peptide on a U-100 insulin syringe.
- Storage
- Lyophilized: store at or below −15°C (5°F)
- Reconstituted: store at 2–8°C (35.6–46.4°F)
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
10mg Blend Vial (5mg CJC-1295 + 5mg Ipamorelin)
2ml BAC water = 5mg/ml concentration
| Protocol | Dose (mcg) / Units | Frequency |
|---|---|---|
| Starting* | 500 mcg (10 Units) | 5x/week |
| Intermediate | 750 mcg (15 Units) | 5x/week |
| Advanced | 1 mg (20 Units) | 5x/week |
Frequency:
Administered 5x per week via subcutaneous injection, most commonly in the evening to align with the body’s natural nighttime growth hormone rhythm.
Dosing Approach:
Many individuals remain at their initial dose for extended periods without increasing, focusing on consistency and tolerance rather than escalation.
Fasted State Recommended:
For best results, avoid food intake for approximately 2–3 hours prior to administration.
Common Sensations:
A temporary warm or flushed feeling in the face may occur shortly after use. This is a commonly reported, short-lived response.
Hydration Matters:
Maintaining adequate water intake is important, as some individuals may experience mild dehydration if fluid intake is insufficient.
Reconstitution Steps
- Draw 2.0 mL of bacteriostatic water using a sterile syringe
- Slowly inject the water into the vial along the inner wall
- Gently swirl or roll the vial until fully dissolved (do not shake)
- Store in the refrigerator (2–8°C), away from light
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan is based on an 8–16 week 5x per week protocol taking the standard dose
10mg Blend Vial (5mg CJC-1295 + 5mg Ipamorelin)
- 8 weeks → 2 vials
- 12 weeks → 3 vials
- 16 weeks → 4 vials
Insulin Syringes
- 8/week total
- 8 weeks → 40
- 12 weeks → 60
- 16 weeks → 80
Bacteriostatic Water
- 8 weeks: ~6 mL (1 bottle)
- 12 weeks: ~9 mL (1 bottle)
- 16 weeks: ~12 mL (2 bottles)
Alcohol Swabs
- 8 weeks → ~40
- 12 weeks → ~60
- 16 weeks → ~80
Protocol Overview
- Goal: Support natural growth hormone release and improve recovery, body composition, and metabolic health
- Schedule: Daily injections for 8–12 weeks (extendable to 16 weeks)
- Dose Range: 500 mcg (250 mcg of each peptide) 5x per week
- Reconstitution: 2.0 mL per vial
- Storage: Refrigerated after mixing; avoid repeated freeze–thaw
Dosing Protocol
Example of a weekly strategy:
Start: 500 mcg (10 Units)
Frequency: Monday – Friday at 11pm, 3 hours after last meal
Cycle Length: 8–12 weeks (optional 16-week extension)
Storage Instructions
Maintaining proper storage conditions is essential for stability.
Lyophilized: Store at ≤−20 °C, dry and protected from light
Reconstituted: Refrigerate (2–8 °C), use within ~2–4 weeks
Avoid repeated freeze–thaw cycles
Allow vial to reach room temperature before opening
Important Notes
Key considerations for consistency and safe handling:
Use a new sterile syringe for each use
Rotate injection sites to minimize irritation
Inject slowly and steadily
Track dosage and timing for consistency
Use smaller syringes for low-volume accuracy
How This Works
CJC-1295 No DAC is a modified GHRH analog that stimulates pulsatile growth hormone release by binding to pituitary receptors. Its short-acting nature allows for controlled GH secretion patterns without prolonged exposure.
Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that triggers GH release through a separate pathway, without significantly affecting cortisol or other hormones in research models.
When combined, these peptides enable the study of:
Dual receptor activation (GHRH + GHS)
Enhanced GH pulsatility
IGF‑1 and IGFBP-3 response patterns
Endocrine feedback regulation
Potential Benefits & Side Effects
Observed Effects in Literature:
Increased GH and IGF‑1 signaling
Improved hormone pulsatility patterns
Selective GH release via Ipamorelin pathway
Synergistic receptor interaction
Reported Reactions (generally mild):
Injection site irritation
Temporary flushing or headache
Occasional appetite changes or fluid retention
Lifestyle Factors
Supporting variables that may improve research consistency:
Maintain structured nutrition protocols for consistency
Include resistance and aerobic activity in study design
Prioritize sleep (linked to GH release cycles)
Control stress variables for hormonal stability
Injection Technique
General guidance for subcutaneous administration:
- Clean the vial stopper and injection area with alcohol and allow to dry
- Gently pinch the skin and insert the needle at a 45–90° angle
- Inject slowly and steadily without aspirating
- Hold the needle in place for a few seconds before removing
- Rotate injection sites (abdomen, thighs, upper arms) to reduce irritation
Recommended Source
We recommend Fit Aminos for high-purity research peptide products CJC-1295 No DAC 5mg+ Ipamorelin 5mg – (10mg Blend)
Why Fit Aminos?
- High-purity, lab-tested peptide batches with quality verification.
- Consistent handling and preparation processes designed to support reliable research protocols.
- Transparent sourcing and dependable fulfillment for research-grade compounds.
Shop for CJC1295/Ipamorelin Blend at Fit Aminos
Important Note
This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment. CJC-1295 No DAC 5mg+ Ipamorelin 5mg – (10mg Blend) remains an investigational peptide with limited human clinical data. For research use only. Not for human consumption.
References
PubMed— Clinical study demonstrating that CJC-1295 significantly increases and sustains growth hormone (GH) and IGF-1 levels in healthy adults.
PubMed— Preclinical research showing that once-daily CJC-1295 restores normal growth patterns in GHRH-deficient animal models
PubMed— Foundational study identifying Ipamorelin as a highly selective growth hormone secretagogue with targeted receptor activity and minimal off-target effects.
PMC (PubMed Central)
— Review exploring the role of growth hormone secretagogues in improving body composition, metabolic function, and endocrine system regulation.
PubMed— Study analyzing the pharmacokinetics and pharmacodynamics of Ipamorelin, including its absorption, distribution, and GH response profile in human subjects.